In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves : a multinational cohort study in the EuCARE project
© 2024 The Author(s)..
Background: Investigating outcomes of hospitalised COVID-19 patients throughout the pandemic is crucial to understand the impact of different SARS-CoV-2 variants. We compared 28-day in-hospital mortality of Wild-type, Alpha, Delta, and Omicron variant infections. Whether the difference in risk by variant varied by age was also evaluated.
Methods: We conducted a cohort study including patients ≥18 years, hospitalised between 2020 and 02-01 and 2022-10-15 with a SARS-CoV-2 positive test, from nine countries. Variant was classified based on sequenced viruses or from national public metadata. Mortality was compared using the cumulative incidence function and subdistribution hazard ratios (SHR) adjusted for age, sex, calendar time, and comorbidities. Results were shown age-stratified due to effect measure modification (P < 0.0001 for interaction between age and variant).
Findings: We included 38,585 participants: 19,763 Wild-type, 6387 Alpha, 3640 Delta, and 8795 Omicron. The cumulative incidence of mortality decreased throughout the study period. Among participants ≥70 years, the adjusted SHR (95% confidence interval) for Delta vs. Omicron was 1.66 (1.29-2.13). This estimate was 1.66 (1.17-2.36) for Alpha vs. Omicron, and 1.34 (0.92-1.95) for Wild-type vs. Omicron. These were 1.21 (0.81-1.82), 1.21 (0.68-2.17), and 0.98 (0.53-1.82) among unvaccinated participants. When comparing Omicron sublineages, the aSHR for BA.1 was 1.92 (1.43-2.58) compared to BA.2 and 1.52 (1.11-2.08) compared to BA.5.
Interpretation: The herein observed decrease in in-hospital mortality seems to reflect a combined effect of immunity from vaccinations and previous infections, although differences in virulence between SARS-CoV-2 variants may also have contributed.
Funding: European Union's Horizon Europe Research and Innovation Programme.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
The Lancet regional health. Europe - 38(2024) vom: 31. März, Seite 100855 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hedberg, Pontus [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 14.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.lanepe.2024.100855 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369664663 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369664663 | ||
| 003 | DE-627 | ||
| 005 | 20240315000001.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lanepe.2024.100855 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM369664663 | ||
| 035 | |a (NLM)38476753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hedberg, Pontus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves |b a multinational cohort study in the EuCARE project |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Author(s). | ||
| 520 | |a Background: Investigating outcomes of hospitalised COVID-19 patients throughout the pandemic is crucial to understand the impact of different SARS-CoV-2 variants. We compared 28-day in-hospital mortality of Wild-type, Alpha, Delta, and Omicron variant infections. Whether the difference in risk by variant varied by age was also evaluated | ||
| 520 | |a Methods: We conducted a cohort study including patients ≥18 years, hospitalised between 2020 and 02-01 and 2022-10-15 with a SARS-CoV-2 positive test, from nine countries. Variant was classified based on sequenced viruses or from national public metadata. Mortality was compared using the cumulative incidence function and subdistribution hazard ratios (SHR) adjusted for age, sex, calendar time, and comorbidities. Results were shown age-stratified due to effect measure modification (P < 0.0001 for interaction between age and variant) | ||
| 520 | |a Findings: We included 38,585 participants: 19,763 Wild-type, 6387 Alpha, 3640 Delta, and 8795 Omicron. The cumulative incidence of mortality decreased throughout the study period. Among participants ≥70 years, the adjusted SHR (95% confidence interval) for Delta vs. Omicron was 1.66 (1.29-2.13). This estimate was 1.66 (1.17-2.36) for Alpha vs. Omicron, and 1.34 (0.92-1.95) for Wild-type vs. Omicron. These were 1.21 (0.81-1.82), 1.21 (0.68-2.17), and 0.98 (0.53-1.82) among unvaccinated participants. When comparing Omicron sublineages, the aSHR for BA.1 was 1.92 (1.43-2.58) compared to BA.2 and 1.52 (1.11-2.08) compared to BA.5 | ||
| 520 | |a Interpretation: The herein observed decrease in in-hospital mortality seems to reflect a combined effect of immunity from vaccinations and previous infections, although differences in virulence between SARS-CoV-2 variants may also have contributed | ||
| 520 | |a Funding: European Union's Horizon Europe Research and Innovation Programme | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a In-hospital mortality | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Variants of concern | |
| 700 | 1 | |a Parczewski, Milosz |e verfasserin |4 aut | |
| 700 | 1 | |a Serwin, Karol |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetti, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Ole Jensen, Björn-Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Joana P V |e verfasserin |4 aut | |
| 700 | 1 | |a Drobniewski, Francis |e verfasserin |4 aut | |
| 700 | 1 | |a Reschreiter, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Naumovas, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccherini-Silberstein, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio Quintanares, Gibran Horemheb |e verfasserin |4 aut | |
| 700 | 1 | |a Mwau, Matilu |e verfasserin |4 aut | |
| 700 | 1 | |a Toscano, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a König, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeifer, Nico |e verfasserin |4 aut | |
| 700 | 1 | |a Zazzi, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Fanti, Iuri |e verfasserin |4 aut | |
| 700 | 1 | |a Incardona, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Cozzi-Lepri, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Sönnerborg, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Nauclér, Pontus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet regional health. Europe |d 2021 |g 38(2024) vom: 31. März, Seite 100855 |w (DE-627)NLM323979734 |x 2666-7762 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g day:31 |g month:03 |g pages:100855 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lanepe.2024.100855 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |b 31 |c 03 |h 100855 | ||